The autoimmune drug developer has received $4.6m from Boehringer Ingelheim Venture Fund to take its series A round to $20.8m.
Boehringer Ingelheim Venture Fund, the corporate venturing subsidiary of pharmaceutical firm Boehringer Ingelheim, has invested €4m ($4.6m) in Germany-based biotechnology developer Topas Therapeutics, allowing it to close its series A round at approximately $20.8m.
Epidarex Capital led the round’s €14m first tranche in March 2016 with participation from EMBL Ventures, the investment arm of research institute European Molecular Biology Laboratory, drug discovery company Evotec and investment firm Gimv.
Topas is working on treatments for autoimmune diseases such as multiple…
